Shots:
- Health Canada has approved ARS Pharma‘s neffy 2mg (adrenaline nasal spray) to treat allergic reactions (anaphylaxis) in adults & children (>30kg)
- In Nov 2024, ARS Pharma granted ALK exclusive rights to commercialize neffy outside the US, incl. EU, Canada, UK, & select markets in exchange for $155M in upfront & milestones till date, ~$310M in regulatory & sale milestones as well as tiered double-digit royalties in the teens
- ARS will supply neffy to ALK in Canada, with launch expected in the summer of 2026. Also, ARS plans to file with Health Canada this summer for neffy 1mg in children (>15 to <30 kg), while joint filings with Pediatrix Therapeutics for the same dose are expected in the coming month in China
Ref: Globenewswire | Image: ARS Pharma |Press Release
Related News: ARS Pharmaceuticals Reports NMPA Approval of neffy 2mg (Epinephrine Nasal Spray) to Treat Type I Allergic Reactions
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
